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Abstract: A growing number of experimental and clinical studies have provided evidence 
indicating that pharmacological blockade of the renin–angiotensin system (RAS) by either 
angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the 
incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular 
disease, independently of antihypertensive and cardiovascular protective effects. The beneficial 
effects of RAS inhibition on the development of diabetes have been largely attributed to improve-
ments in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent 
experimental and clinical evidence supporting the role of RAS inhibition in the reduction of 
new onset type 2 diabetes and the mechanisms that may be involved.
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Introduction
According to the World Health Organization (WHO), more than 19 million adults in 
the US and 150 million adults worldwide have type 2 diabetes.1 It is projected that 
there will be more than 300 million cases worldwide by the year 2025.1 Diabetics have 
a two-fold higher risk of cardiovascular morbidity than nondiabetic individuals.2 In 
addition, the prevalence of hypertension, an established risk factor for the development 
and progression of cardiovascular disease, is increasing in the US.3,4 It is estimated 
that hypertension affects 20% of the adult population and over 20 million adults in 
the US are receiving antihypertensive treatment.5
Of  note, hypertension has been associated with an increased risk for the development 
of type 2 diabetes. About 50% of hypertensive individuals have hyperinsulinemia or 
glucose intolerance, whereas up to 80% of type 2 diabetic patients have hypertension.6 
The association of hypertension with diabetes entails a greater increase in the risk of 
cardiovascular disease. Moreover, most patients with type 2 diabetes have insulin 
resistance, a condition that may precede the diagnosis of diabetes by up to 20 years.7 
Clinical studies have shown that insulin resistance and hypertension are often asso-
ciated and are central features of the metabolic syndrome, a significant risk factor 
for cardiovascular morbidity and mortality that affects over 40 million adults in the 
United States.8
Antihypertensive agents may exert negative, neutral, or positive metabolic 
effects.9,10 Accumulating evidence suggests that the use of agents that impair glucose 
tolerance constitutes a risk factor for the development of type 2 diabetes.10,11 Thus, 
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type 2 diabetes (NOD) in patients receiving antihypertensive 
treatment constitute major health care challenges. There is 
now general agreement that therapeutic strategies should 
be assessed on the basis of prospective clinical trials pre-
stratified for diabetes.
An increasing number of clinical studies,12–15 including 
the Valsartan Antihypertensive Long-term Use Evaluation 
(VALUE) trial,16,17 have provided evidence indicating that 
pharmacological blockade of the renin–angiotensin system 
(RAS) reduces the incidence of NOD in high-risk patients 
with cardiovascular disease. The beneficial effects of RAS 
inhibition on the development of diabetes have been largely 
attributed to improvements in peripheral insulin sensitivity 
and glucose metabolism.18,19 This review focuses on recent 
clinical and experimental evidence supporting the role of 
RAS inhibition in the reduction of NOD and the mechanisms 
that may be involved.
Prevention of diabetes by RAS 
inhibition: Evidence from clinical 
studies
Multiple large prospective trials have reported an unexpected 
reduction in the development of NOD in patients treated 
with certain antihypertensive agents.3,12,16,20 These trials 
predominantly used angiotensin-converting enzyme (ACE) 
inhibitors and angiotensin receptor blockers (ARBs) and 
reported a reduction in the risk of NOD ranging from 15% 
to 35%.12,13,16,21
The VALUE16,17,22 trial was designed to compare cardiac 
outcomes in treatment regimens based on the ARB valsartan 
and the calcium channel blocker (CCB) amlodipine in a popu-
lation of essential hypertensive patients recruited according 
to a specific predefined age- and risk factor-dependent algo-
rithm. A total of 15,245 high-risk patients were followed for 
an average of 4.2 years. The results showed that there was 
no difference between the two drug regimens in the primary 
composite cardiac endpoint rate or in all-cause mortality.16 
However, the relative risk of NOD, a pre-specified secondary 
end point, was 23% lower in the group receiving valsartan 
than in the amlodipine group.16,17,22 New diabetes was 
reported in 580 (11.5%) patients in the valsartan group and 
in 718 (14.5%) patients in the amlodipine group. In absolute 
terms, valsartan reduced NOD by 3% compared with amlo-
dipine.17 This finding confirms and extends the results of the 
Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT).23 In the ALLHAT study, the 
incidence of NOD in patients treated with the ACE inhibitor 
lisinopril was reduced by 30% compared with the thiazide 
diuretic chlorthalidone and by 17% compared with the CCB 
amlodipine. Based on the available experimental and clinical 
evidence, it has been proposed that RAS inhibitors exert a 
positive metabolic effect in terms of improvement in glucose 
intolerance and insulin resistance,9 CCBs exert a neutral 
metabolic effect, whereas diuretics and β-blockers exert 
negative metabolic effects.24,25 The ALLHAT and VALUE 
trials compared RAS inhibitors with the metabolically neutral 
amlodipine.12,16 The results of both trials support the notion 
that reduction in the incidence of NOD by RAS inhibitors is 
likely due to a direct beneficial effect of RAS blockade rather 
than a detrimental effect of the comparator drug.
The findings from the VALUE trial showing that RAS 
inhibition prevents the development of diabetes has been 
supported by a number of clinical studies.20,26,27 A recent 
meta-analysis of 13 randomized trials was done to determine 
if ACE inhibitors and/or ARBs prevent the development of 
type 2 diabetes.3 These trials enrolled 92,408 patients without 
diabetes, of whom 41,950 were randomized to treatment 
with an ACE inhibitor or ARB, while the remainder received 
active control (CCBs, thiazide diuretics, or β-blockers) 
or placebo. Nine of these trials randomized hypertensive 
patients. In this group, RAS inhibition resulted in a 27% 
reduction in the relative risk of NOD. NOD developed in 
7.1% of patients on ACE inhibitors or ARBs versus 9.0% 
of patients on placebo or other antihypertensive agent. Four 
of the trials randomized patients with vascular disease or 
left ventricular dysfunction. RAS inhibition reduced the 
incidence of NOD by 33%. Diabetes developed in 6.7% of 
patients treated with an ACE inhibitor or ARB, compared 
with 8.5% of patients on placebo or other agents. ACE inhibi-
tors and ARBs had comparable effects on the development 
of diabetes. These clinical trials provide evidence that RAS 
inhibition with either ACE inhibitors or ARBs contributes 
to the prevention of diabetes.
According to the results from the Anglo-Scandinavian 
Cardiac Outcomes Trial – Blood Pressure Lowering Arm 
(ASCOT-BPLA), hypertensive individuals who have elevated 
fasting plasma glucose, triglycerides, or body mass index at 
baseline are at risk for the development of type 2 diabetes.28 
These patients may benefit from the use of antihypertensive 
agents endowed with positive metabolic effects, such as ACE 
inhibitors or ARBs, or with metabolically neutral agents, such 
as CCBs, for the treatment of hypertension.
Of note, although substantial clinical evidence supports 
the notion that inhibition of RAS reduces the incidence 
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disease, the results from the Diabetes REduction Assessment 
with ramipril and rosiglitazone Medication (DREAM) trial 
showed that in patients with impaired glucose tolerance 
the ACE inhibitor ramipril did not significantly reduce the 
incidence of NOD (18.1%) after three years of follow-up 
compared with placebo (19.5%).29,30 Because patients with 
cardiovascular disease or uncontrolled hypertension were 
excluded from the DREAM trial, one possible explanation 
for the discrepancy between the DREAM trial and other 
clinical trials is the difference between the patient popula-
tions studied. However, participants receiving ramipril were 
more likely to have regression to normoglycemia than those 
receiving placebo (hazard ratio [HR] 1.16; 95% confidence 
interval [CI], 1.07 to 1.27; p = 0.001). In addition, at the end 
of the study, plasma glucose levels two hours after an oral 
glucose load were significantly lower in the ramipril group 
(135.1 mg per deciliter [7.50 mmol per liter] vs 140.5 mg 
per deciliter [7.80 mmol per liter]; p = 0.01).
Most clinical trials, including the ALLHAT and VALUE 
trials, failed to detect a greater reduction in cardiovascular 
endpoints in patients treated with ACE inhibitors or ARBs 
compared with other agents.12,13,16,31 This raised the question 
of whether prevention of NOD by ACE inhibitors or ARBs 
translates into improvement in cardiovascular morbidity and 
mortality. Using previous data on the number of subjects 
needed to treat and to prevent one case of NOD and the 
estimated incidence of cardiovascular events, Verdecchia 
and colleagues calculated how many cardiovascular events 
specifically associated with NOD may be prevented by 
“new” (RAS inhibitors and CCBs) versus “old” (diuretics 
and β-blockers) antihypertensive agents.32 They reported 
that one NOD-associated cardiovascular event might be 
prevented for every 385 to 449 subjects treated with new 
rather than old antihypertensive agents for approximately 
four years. Therefore, the attempt to draw solid implications 
on the prognostic value of NOD from these randomized trials 
may be limited by the inadequacy of sample size and not by 
the lack of adverse prognostic value of NOD itself. Indeed, 
a recent post-hoc analysis of the VALUE trial database2 
showed that patients with diabetes at baseline had higher 
cardiovascular morbidity (HR 2.2) than patients without 
diabetes. Patients who developed diabetes during antihyper-
tensive treatment had a cardiovascular morbidity that was 
intermediate (HR 1.43) between diabetic and nondiabetic 
subjects. These results indicate that NOD predicts an excess 
risk of cardiovascular events33 and it is important to identify 
patients at risk of developing diabetes in order to optimize 
lifestyle and medical interventions.
Mechanisms underlying 
the reduction in incidence 
of NOD by RAS blockade
The mechanisms underlying the prevention of NOD by RAS 
blockade are complex and not fully elucidated. Mechanisms 
that have been proposed include stimulation of intracellular 
insulin signaling in insulin-sensitive and vascular tissues,34,35 
improvement of microvascular endothelial function leading 
to increased blood flow and glucose delivery and disposal 
in skeletal muscle,36,37 improvement of pancreatic β-cell 
function resulting in enhanced insulin secretion in response 
to glucose stimulation,38 and modulation of adipose tissue 
hormonal responses39,40 (Figure 1).
Stimulation of insulin signaling 
in insulin-sensitive tissues and vascular cells
Insulin and angiotensin II are two important hormones in 
the control of metabolic and hemodynamic homeostasis, 
respectively. Recent studies have suggested that the signal 
transduction pathways of insulin and angiotensin II share a 
number of downstream effectors and cross-talk at multiple 
levels.41 In pathophysiologic conditions such as hypertension 
and diabetes, activation of RAS inhibits insulin signaling in 
insulin sensitive tissues as well as vascular cells,42 resulting in 
development of insulin resistance and progression of cardio-
vascular disease. Inhibition of RAS by either ACE inhibitors 
or ARBs has been shown to improve insulin signaling and 
insulin sensitivity in clinical43 and experimental studies.35
The insulin signaling pathway is initiated by circulating 
insulin binding to its receptor, after which the insulin receptor 
undergoes rapid tyrosine autophosphorylation that activates 
the receptor kinase and allows transient interaction with 
insulin receptor substrates (IRSs). Interaction of tyrosine 
phosphorylated IRS-1 with the p85 regulatory subunit of 
phosphatidylinositol 3-kinase (PI3K) results in activation 
of PI3K and phosphorylation of Akt.44 Phosphorylated Akt 
stimulates translocation of Glut-4 to the sarcolemma to 
facilitate glucose entry into the cell. Intracellular glucose is 
then rapidly phosphorylated by hexokinase and directed to 
oxidative or nonoxidative pathways.45
It has been shown that angiotensin II exerts an inhibitory 
effect on insulin stimulation of the PI3K pathway.41 In 
cultured L6 myocytes, angiotensin II stimulates serine-
phosphorylation of IRS-1.46 IRS-1 is one of the major 
substrates of the insulin receptor kinase and contains 
multiple tyrosine phosphorylation motifs that serve as 
docking sites for SH2 domains that mediate the metabolic and Vascular Health and Risk Management 2009:5 364
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growth-promoting functions of insulin. IRS-1 also contains 
over 30 potential serine/threonine phosphorylation sites. 
Phosphorylation of IRS-1 at serine/threonine inhibits 
insulin stimulation of tyrosine phosphorylation, resulting 
in inhibition of downstream insulin signaling molecules.47 
It has been shown that phosphorylation of IRS-1 at Ser 
612 (human Ser616) and Ser307 (human Ser312) inhibits 
the insulin/PI3K signaling pathway.47 The phosphorylation 
of IRS-1 at Ser612 causes dissociation of the p85 subunit 
of PI3K, inhibiting downstream signaling, whereas the 
phosphorylation of IRS-1 on Ser307 results in its disso-
ciation from the insulin receptor and triggers proteasome-
dependent degradation. It has been shown that angiotensin II 
induces serine phosphorylation at both sites and inhibits 
downstream signaling, including Akt phosphorylation and 
Glut-4 translocation to the sarcolemma, therefore inhibiting 
glucose uptake. The underlying mechanisms may involve 
angiotensin II stimulation of reactive oxygen species (ROS) 
production.35,46,48
In the vasculature, insulin stimulates phosphorylation of 
endothelial nitric oxide synthase (NOS) at Ser1179 through 
activation of the PI3K pathway, resulting in nitric oxide 
(NO)-mediated vasorelaxation, which increases blood flow 
and glucose delivery to the skeletal muscle.37,49 NO exerts 
important vasoprotective effects in the cardiovascular system. 
Thus, constitutive stimulation of NO production by insulin 
may play an important role in the maintenance of vascular 
health as well as regulation of glucose metabolism.49 It has 
been shown that in vascular endothelial cells, angiotensin 
II, by interfering with the PI3K signaling pathway, impairs 
insulin stimulation of NO production.49 In addition, insulin 
stimulates the mitogen-activated protein kinase (MAPK) 
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Figure 1 Schemata of mechanisms underlying the prevention of diabetes development by inhibition of the renin–angiotensin system (RAS). Hypertension (HTN) and 
cardiovascular (CV) risk factors are commonly associated with activation of the RAS. Activation of angiotensin ii produces the following biological effects: 1) inhibition of 
insulin activation of the phosphatidylinositol 3-kinase (Pi3K) signaling pathway; 2) inhibition of pre-adipocyte differentiation into mature adipocytes, leading to reduction in 
secretion of adiponectin and increase in inflammatory cytokine production; 3) increased reactive oxygen species (ROS) production, resulting in islet structural damage and 
β-cell dysfunction; 4) activation of the mitogen-activated protein kinase (MAPK) pathway, leading to vascular remodeling and promotion of CV disease. All of these biological 
effects cause impairment of glucose metabolism and insulin resistance, thus contributing to the development of diabetes. inhibition of RAS by either angiotensin converting 
enzyme inhibitors (ACei) or angiotensin ii type 1 receptor blockers (ARB) prevents these detrimental effects of angiotensin ii on glucose metabolism and insulin resistance, 
therefore potentially reducing the development of diabetes and cardiovascular complications.
Abbreviation: iRS1, insulin receptor substrate-1.Vascular Health and Risk Management 2009:5 365
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pathway to promote cellular growth and migration.49 In 
insulin resistant states such as hypertension and diabetes, 
insulin-stimulation of the PI3K pathway is selectively 
impaired and overactivation of RAS and hyperinsulinemia 
may synergistically stimulate the MAPK pathway, which 
may contribute to the development of cardiovascular compli-
cations. Inhibition of angiotensin II, by either ACE inhibition 
or angiotensin receptor blockade, improves insulin activation 
of the PI3K pathway, thus facilitating Glut-4 translocation 
and glucose uptake in insulin-sensitive tissues and enhanc-
ing NO-mediated vasorelaxation. The increased capillary 
recruitment, blood flow, and glucose disposal in skeletal 
muscle improve systemic insulin sensitivity and potentially 
reduce cardiovascular complications.
improvement of glucose metabolism
As described above, angiotensin II has an inhibitory effect on 
insulin-mediated PI3K activation, which is mainly mediated 
by activation of the angiotensin II type 1 (AT1) receptor. 
Experimental studies have shown that the chronic admin-
istration of ARBs significantly improve systemic glucose 
metabolism in various animal models of insulin resistance, 
including the obese Zucker rats, spontaneously hyperten-
sive rats, and fructose-fed rats.50,51 The Dahl salt-sensitive 
(DS) rat is an animal model of salt-induced hypertension 
and cardiovascular disease. We have demonstrated that 
the hypertensive DS rat manifests metabolic insulin resis-
tance, determined by hyperinsulinemic euglycemic clamp, 
impaired endothelium-dependent relaxation to acetylcholine 
and insulin, accompanied by increased vascular superoxide 
production.35,52 Treatment with the ARB candesartan or 
antioxidant tempol improved systemic insulin sensitivity 
and acetylcholine- and insulin-mediated vasorelaxation, 
suggesting that angiotensin II-mediated ROS overproduc-
tion interferes with insulin signaling pathways in both 
metabolic and cardiovascular tissues in this hypertensive 
animal model.35
The skeletal muscle is the largest insulin-sensitive tissue 
in the body and primary site for insulin-stimulated glucose 
metabolism. The skeletal muscle comprises 40%–50% of 
body mass and handles over 75% of insulin-mediated glu-
cose disposal.45,53 Studies with rodent models suggest that 
angiotensin II may play an important role in the etiology of 
skeletal muscle insulin resistance. For example, systemic or 
local infusion of angiotensin II produced insulin resistance 
in skeletal muscle independent of hemodynamic effects.42,54 
Studies in TG(mREN2)27 rats,53 which harbor the mouse 
Ren-2 renin gene and are a transgenic model with elevation 
of systemic and local (skeletal muscle) angiotensin II levels,55 
have shown that they exhibit whole-body and skeletal 
muscle insulin resistance, associated with enhanced ROS 
production and defective activation of the IRS-1/PI3K/Akt 
pathway.53,56 Furthermore, tempol improved insulin sensi-
tivity and insulin-mediated glucose uptake in the skeletal 
muscle, suggesting that angiotensin II impairs insulin action 
on skeletal muscle glucose metabolism at least in part through 
generation of ROS.
Protection of pancreatic β-cell function
It has been shown that the pancreas expresses all components 
of the RAS, which modulates a range of activities includ-
ing local blood flow, hormone release, and prostaglandin 
synthesis. Activation of the local (islet) RAS may increase 
oxidative stress, inflammation, and free fatty acid levels, 
which potentially contributes to β-cell dysfunction in dia-
betes.57 Experimental studies have provided evidence that 
blockade of RAS improves islet structure and function by 
increased blood flow and oxygen tension and inhibition of 
oxidative injury.39,58,59 Tikellis and colleagues58 showed that 
blockade of RAS by either an ACE inhibitor (perindopril) 
or ARB (irbesartan) attenuated islet fibrosis, apoptosis, 
and oxidative stress in Zucker diabetic fatty rats, a type 2 
diabetic animal model. In the db/db mouse model, chronic 
AT1 receptor blockade decreased NADPH oxidase-induced 
oxidative stress and downregulated expression of mitochon-
drial uncoupling protein 2 (UCP2), which is associated with 
improved β-cell insulin secretion and reduced apoptosis-
induced β-cell mass loss.60 Interestingly, recent studies 
also showed that hyperglycemia can activate the RAS in 
pancreatic islet and stellate cells.57 Therefore, RAS blockade 
may ameliorate the angiotensin II-induced pancreatic inflam-
mation and fibrosis aggravated by chronic exposure to high 
glucose levels.
Modulation of adipocytokines
Obesity is a common cause of insulin resistance and one 
of the strongest risk factors for the development of type 2 
diabetes.61 The increasing prevalence of obesity has largely 
contributed to the increasing incidence of type 2 diabetes 
and cardiovascular disorders.61 Adipose tissue does not 
only store energy, but is increasingly recognized as an 
active endocrine and paracrine organ that produces and 
releases a large number of cytokines and bioactive media-
tors that are collectively referred to as adipocytokines.62,63 
Some adipocytokines, such as tumor necrosis factor-α 
(TNF-α) and nuclear factor kappa B (NFκB), can inhibit Vascular Health and Risk Management 2009:5 366
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insulin signaling and exert diabetogenic effects, whereas 
other adipocytokines,64,65 such as adiponectin, exert 
antidiabetic effects. Adiponectin appears to be secreted 
in higher levels by small (differentiated) adipocytes and 
found circulating in lower levels in patients with essential 
hypertension or type 2 diabetes.66 Large adipocytes 
produce diabetogenic adipocytokines, such as TNF-α 
and plasminogen activator inhibitor (PAI)-1, secrete less 
adiponectin, and cause insulin resistance. Considering 
that inhibition of angiotensin II reduces the incidence of 
type 2 diabetes and that adipocytes express all components 
of the RAS, including angiotensinogen, ACE, AT1, and 
AT2 receptors, it has been proposed that blockade of 
RAS may promote the recruitment and differentiation 
of pre-adipocytes and increased formation of small 
insulin-sensitive adipocytes, thereby improving insulin 
sensitivity.66 Indeed, several recent studies have provided 
evidence showing that angiotensin II inhibits adipogenic 
differentiation of human adipocytes via the AT1 receptor67 
and inhibition of angiotensin II by ACE inhibitors or 
ARBs increases the number of small differentiated insulin 
sensitive adipocytes and decreases large adipocytes.38,40,67 
In the OLEFT rat, a model of type 2 diabetes, Lee and 
colleagues38 showed that treatment with an ARB improves 
the differentiation of adipocytes and inhibits activation of 
the inflammatory process in adipose tissue, accompanied 
by an increase in adiponectin and a decrease in NFκB, 
PAI-1, and monocyte chemoattractant protein-1. Therefore, 
the modulation of adipocytokine production by blockade 
of RAS may be another mechanism for the prevention of 
diabetes.
Conclusion
Accumulating experimental evidence indicates that activation 
of the RAS plays an important role in the development of 
insulin resistance, glucose intolerance, and type 2 diabetes.19,41 
Although clinical studies are needed to confirm these exper-
imental findings, a growing number of clinical trials support 
the notion that RAS blockade exerts antidiabetogenic effects 
in patients with hypertension and cardiovascular disease.18,68 
Further research is necessary to identify patients at risk for 
development of diabetes and other cardiovascular com-
plications and those who would most benefit from RAS 
blockade.
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